The biopharmaceutical contract manufacturing market is projected to grow from USD 11.23 billion in 2025 to USD 26.93 billion by 2035 at a CAGR of 8.8%. Growth is being driven by limited in-house capabilities and the rising complexity of biologics. Mammalian-based expression systems will account for 72.5% of global market share in 2025. Increased adoption of outsourced services is linked to the specialized requirements of monoclonal antibodies, vaccines, and gene therapies. China, India, and Japan projected as the fastest-growing regions over the forecast period.
Infrastructure expansion and strategic partnerships have been prioritized. Thermo Fisher Scientific announced on 14 April 2025 the expansion of its biologics facility in Hangzhou, China, to meet regional demand. These investments have been driven by increasing volume requirements and a shift toward cell and gene therapy pipelines. Sartorius reported in its 2025 white paper the commercial-scale integration of single-use bioreactors to accelerate clinical and commercial output.
Complex batch processes, high capital barriers, and inconsistent regulatory standards have limited capacity scale-up in some markets. According to the Biopharmaceutical Manufacturing and Quality Alliance on 2 May 2025, global alignment of quality frameworks remains incomplete. Still, the USA FDA’s 2025 CMC guideline revision has supported contract manufacturers in meeting accelerated approval timelines. By 2035, mammalian systems will remain dominant, while microbial-based platforms gain adoption for cost-sensitive biologics.
Leading CMOs are actively pursuing vertical integration to offer end-to-end capabilities, from early-phase development to commercial-scale production. This model reduces time-to-market and regulatory friction for biopharma clients. Lonza, Samsung Biologics, and WuXi Biologics have each announced modular facility frameworks in 2025 that enable flexible scaling and multi-product handling. This trend is reshaping the competitive landscape by favoring CMOs that can align with the rapid iteration cycles of mRNA platforms and personalized cell therapies. Meanwhile, mid-sized firms are differentiating through niche expertise-such as high-potency APIs or fill-finish services-rather than competing on volume.
| Attributes | Details |
|---|---|
| Market Size, 2025 | USD 11.23 billion |
| Market Size, 2035 | USD 26.93 billion |
| Value CAGR (2025-2035) | 8. 8 % |
The biopharmaceutical contract manufacturing market is segmented comprehensively-by Platform Type: mammalian based and microbial based; by Product Type: monoclonal antibodies, recombinant protein, vaccine, insulin, growth factor, interferons, and others; by Application Type: clinical and commercial; by Therapeutic Area Type: autoimmune diseases, oncology, metabolic diseases, ophthalmology, cardiovascular diseases, infectious diseases, neurology, respiratory disorders, and others; and by Region: North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia, and the Middle East & Africa.
Among the different methods used to make biopharmaceuticals, mammalian-based systems will continue to lead in value growth through 2035. Starting from a global market size of USD 11.23 billion in 2025, this segment is expected to grow to USD 26.93 billion by 2035. Of this, mammalian systems will contribute around USD 8.12 billion in 2025—about 72.3% of the total—and are projected to reach USD 19.92 billion by 2035, growing at a rate of 9.1% each year. On the other hand, microbial-based systems-though cheaper-will grow more slowly and play a smaller role. They are expected to grow from USD 3.11 billion in 2025 to USD 7.01 billion by 2035, with an annual growth rate of 8.1%. These systems are still important for producing items like insulin and enzymes. But they are less suitable for many modern biologic drugs and aren’t as profitable in smaller, highly specialized markets. By 2035, mammalian-based systems will remain the backbone of high-value therapies, while microbial systems will still be useful for more basic and cost-sensitive drugs.
| Platform Type | CAGR 2025-2035 |
|---|---|
| Mammalian-Based | 9.1% |
| Microbial-Based | 8.1% |
Monoclonal antibodies (mAbs) will remain the biggest source of revenue in the biopharmaceutical contract manufacturing market through 2035. Out of the total USD 11.23 billion market in 2025, mAbs are expected to make up about USD 4.93 billion, roughly 44% of total demand. This figure is projected to grow to USD 12.95 billion by 2035, showing a strong annual growth rate of 10.2%. Recombinant proteins, used in areas like hormone therapy and blood disorders, will also grow steadily, from USD 2.04 billion in 2025 to USD 4.19 billion by 2035. The expected annual growth rate is 7.6%, driven by consistent medical demand, though profit margins may stay lower due to more standardized production processes. Vaccine manufacturing is set to grow rapidly, especially with mRNA and protein-based vaccines expanding beyond COVID-19. This segment is expected to grow from USD 1.62 billion in 2025 to USD 3.61 billion by 2035, at an annual growth rate of 8.7%. National vaccination programs and wider use in preventing infectious diseases will support this growth. Insulin and growth factors, mostly made using microbial systems, will see modest growth-with CAGRs of 6.4% and 6.9% respectively. Rising demand in developing countries and growing numbers of people with diabetes will drive this increase. Meanwhile, interferons and similar biologic drugs will grow more slowly. They are losing importance in drug pipelines and are being replaced by newer treatments, leading to below-average growth.
| Product Type | CAGR 2025-2035 |
|---|---|
| Monoclonal Antibodies | 10.2% |
| Recombinant Protein | 7.6% |
Commercial-scale manufacturing will generate the largest share of revenue in the biopharmaceutical contract manufacturing market by 2035. From the expected global market of USD 11.23 billion in 2025, around USD 6.86 billion, or roughly 61.1%, will come from commercial production. This is projected to grow to USD 17.50 billion by 2035, with an annual growth rate of 9.9%. This strong performance is largely driven by the steady expansion of approved biologic drugs in areas like cancer, autoimmune conditions, and chronic diseases. Large pharmaceutical and biotech companies are also outsourcing more of their commercial production to cut down on investment costs and reduce regulatory challenges. Additionally, many companies are extending the life of existing products through strategies like reformulations and new versions, which keeps commercial production going even after a product's initial launch.Clinical manufacturing, while smaller in market size, plays a crucial role in early-stage drug development and fast-track regulatory pathways. This segment is expected to grow from USD 4.37 billion in 2025 to USD 9.43 billion by 2035, reflecting an annual growth rate of 7.9%. Its growth is supported by a rising number of new drug applications and the need for flexible facilities that can handle small, specialized batches. However, clinical manufacturing earns less revenue than commercial manufacturing because it involves shorter production runs, lower volumes, and a higher risk that the drug may not make it to market.As more biologic drugs receive approval and new treatment areas open up, commercial-scale outsourcing will continue to drive the bulk of growth. By 2035, this segment is expected to contribute nearly two-thirds of all value in the contract manufacturing market.
| Application Type | CAGR 2025-2035 |
|---|---|
| Commercial | 9.9% |
| Clinical | 7.9% |
The biopharmaceutical contract manufacturing market, valued at USD 11.23 billion in 2025 and expected to reach USD 26.93 billion by 2035, will be driven most strongly by oncology applications. Manufacturing for oncology drugs is projected to generate USD 3.89 billion in 2025 and grow to USD 10.96 billion by 2035, reflecting an annual growth rate of 10.7 percent. This expansion is being fueled by a strong pipeline of cancer treatments, widespread use of monoclonal antibodies and antibody-drug conjugates, and the growing need for specialized contract manufacturers to handle complex therapies that require mammalian cell systems and meet strict regulatory standards.
Autoimmune diseases will also show strong growth, as more companies outsource production for long-term biologic treatments used in conditions like rheumatoid arthritis and Crohn’s disease. This segment is expected to grow at an annual rate of 9.1 percent. Infectious diseases will follow, supported by continued vaccine development and the flexibility of platforms like mRNA. The infectious disease segment is projected to increase from USD 1.82 billion in 2025 to USD 4.07 billion by 2035, growing at 8.4 percent each year.
Neurology and metabolic diseases will remain steady mid-growth areas, helped by demand for gene and enzyme therapies. Ophthalmology and cardiovascular treatments will grow more slowly but still play a role in outsourcing, particularly for specialized or niche products. Meanwhile, respiratory disorders and other therapeutic areas are expected to see the slowest growth, as there has been less biologic innovation in these fields.
| Therapeutic Area | CAGR 2025-2035 |
|---|---|
| Oncology | 10.7% |
| Autoimmune Diseases | 9.1% |
The United States will retain its position as the dominant profit pool in the global biopharmaceutical contract manufacturing market, with revenue projected to rise from USD 3.95 billion in 2025 to USD 8.41 billion by 2035, reflecting a CAGR of 7.8%. The USA continues to house the most mature biologics innovation ecosystem globally, with over 45% of global late-stage biologic trials headquartered domestically. This fuels sustained clinical and commercial outsourcing demand, particularly in monoclonal antibodies, ADCs, and cell therapies. Further, regulatory alignment is strong: the USA. FDA’s 2025 overhaul of CMC guidance reduced pre-approval inspection bottlenecks and incentivized sponsor-CDMO alignment early in the development lifecycle. Also, CDMOs operating within major biotech corridors-Massachusetts, California, and North Carolina-benefit from local talent density, proximity to sponsors, and favorable infrastructure. However, operational risks include rising wage inflation across biomanufacturing roles and regional variations in GMP audit standards. Additionally, ESG compliance costs may pressure EBITDA margins as California, in particular, enforces tighter environmental controls. Despite these headwinds, USA based CDMOs are expected to maintain high capacity utilization levels, benefiting from multi-year manufacturing agreements and lifecycle production of high-margin biologics.
| 2025 Value (USD billion) | CAGR 2025-2035 |
|---|---|
| 3.95 | 7.8% |
China is expected to be the fastest-expanding national market in the biopharmaceutical contract manufacturing landscape, scaling from USD 0.91 billion in 2025 to USD 3.32 billion by 2035, registering a CAGR of 13.7%. China’s government-backed “Biotech 2030” framework has made biomanufacturing a priority sector, offering tax relief, land access, and soft capital to CDMOs investing in GMP-compliant infrastructure. Regulatory transformation is proving pivotal. The National Medical Products Administration (NMPA) has aligned its technical review framework with ICH guidelines, creating cross-border trust in Chinese CDMO output. Domestic biopharma demand is intensifying-China now leads globally in new IND filings for biosimilars and PD-1 inhibitors. Infrastructure in Suzhou, Shanghai, and Guangzhou is rapidly scaling, with regional CDMOs expanding their mammalian cell capacity and investing in single-use bioreactor lines. Risk factors include quality inconsistencies among smaller players and fragmented GMP audit standards between provinces. Nonetheless, foreign sponsors are increasingly sourcing early-stage and biosimilar manufacturing from China to benefit from 30-40% cost advantages. With regulatory credibility rising and internal biologics consumption booming, China is forecast to capture a growing share of global outsourcing mandates.
| 2025 Value (USD billion) | CAGR 2025-2035 |
|---|---|
| 0.91 | 13.7% |
Germany remains the cornerstone of biopharmaceutical contract manufacturing in Western Europe, with the market estimated to expand from USD 0.88 billion in 2025 to USD 1.94 billion by 2035, registering a steady CAGR of 8.2%. Three fundamentals underpin its trajectory. First, Germany hosts some of the EU’s most advanced biomanufacturing infrastructure, anchored by a strong legacy in chemical engineering and pharmaceutical scale-up. CDMOs in cities like Munich, Heidelberg, and Frankfurt are heavily invested in mammalian and microbial systems, positioning them to service monoclonal antibodies, vaccines, and biosimilars. Second, Germany benefits from an export-oriented biologics economy. Over 60% of its CDMO output is destined for global supply chains, supported by mature logistics and stringent EU-GMP compliance. Third, regulatory stability and access to high-skill labor continue to enhance the investment climate. However, downside risks persist. Energy volatility, particularly since 2022, remains a cost-management challenge for temperature- and pressure-sensitive biomanufacturing processes. Additionally, wage inflation in Germany’s technical sectors may compress long-term margins. Even so, high trust in German GMP standards, combined with the country’s central location within EU pharma logistics, ensures it remains a preferred outsourcing destination for USA. and Japanese sponsors seeking access to EMA-aligned production pathways.
| 2025 Value (USD billion) | CAGR 2025-2035 |
|---|---|
| 0.88 | 8.2% |
Japan’s biopharmaceutical contract manufacturing market is poised for solid expansion, growing from USD 0.76 billion in 2025 to USD 1.56 billion by 2035, at a CAGR of 7.5%. The outlook is supported by several regulatory and structural levers. Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has increased alignment with ICH harmonization protocols, particularly in process validation and biologics licensing, making it easier for multinational sponsors to engage Japanese CDMOs. Japan’s aging population and corresponding biologics demand, especially in oncology and autoimmune disorders, are triggering more domestic outsourcing as local biotechs and pharma firms reduce capital expenditure on in-house facilities. Japanese CDMOs enjoy a reputation for high precision and low deviation rates, particularly in aseptic fill-finish operations and microbial fermentation. Challenges remain. Japan faces acute labor shortages in biomanufacturing, particularly outside major hubs like Tokyo and Osaka, and cost competitiveness is often eclipsed by regional peers in South Korea and China. However, Japan’s CDMOs continue to win long-term contracts from global sponsors focused on quality-sensitive therapeutic segments. The overall growth trajectory is stable, with rising demand for complex biologics and steady investment in modular capacity enhancements.
| 2025 Value (USD billion) | CAGR 2025-2035 |
|---|---|
| 0.76 | 7.5% |
India is rapidly consolidating its position as a global cost-efficiency hub for biopharmaceutical contract manufacturing, with the market expected to grow from USD 0.72 billion in 2025 to USD 2.26 billion by 2035, reflecting a CAGR of 12.1%. Three strategic enablers shape this growth. India’s existing strength in generic drug manufacturing is being leveraged into biologics, with major CDMOs in Hyderabad, Bengaluru, and Pune investing heavily in bioreactor capacity and single-use systems. Regulatory reforms under the Central Drugs Standard Control Organization (CDSCO) have streamlined GMP certification and technology transfer processes, reducing onboarding time for international sponsors. India's labor and utility cost advantages remain unparalleled, with 30-40% savings over Western CDMOs, enabling it to win early-stage, scale-up, and biosimilar mandates from global biotech firms. However, challenges remain: regulatory harmonization with ICH continues to lag in consistency, and perception risks around quality compliance persist-especially for sterile fill-finish operations. Nonetheless, several top-tier Indian CDMOs have secured USA FDA and EMA approvals, boosting global confidence. As biologics penetration rises in domestic therapy areas (oncology, autoimmune, diabetes), internal demand is also beginning to complement export-led growth, reinforcing India’s dual-role value in the outsourcing value chain.
| 2025 Value (USD billion) | CAGR 2025-2035 |
|---|---|
| 0.72 | 12.1% |
The United Kingdom continues to deliver stable, innovation-led performance in the biopharmaceutical contract manufacturing sector, with the market forecast to grow from USD 0.69 billion in 2025 to USD 1.47 billion by 2035, representing a CAGR of 7.9%. The UK’s appeal rests on three foundational strengths. First, proximity to Oxford-Cambridge-London’s “Golden Triangle” offers CDMOs high-density access to early-stage biotech pipelines and translational medicine programs, enabling fast technology transfer and pilot-scale production. Second, the UK Medicines and Healthcare products Regulatory Agency (MHRA) has proven agile post-Brexit, updating GMP frameworks to remain competitive with EMA and FDA pathways while offering localized regulatory support. Third, the government’s Life Sciences Vision (2021-2031) earmarked over GBP 1 billion in incentives for advanced therapy manufacturing, catalyzing investment in viral vector, plasmid DNA, and mRNA infrastructure. However, the post-Brexit operating environment still creates frictions, especially in cross-border clinical trial sourcing and batch release logistics. Wage inflation and energy costs are further pressuring margin structures. Despite this, the UK remains a high-trust environment for quality-sensitive manufacturing-particularly for oncology and cell therapies-making it an attractive destination for global sponsors seeking reliability over scale.
| 2025 Value (USD billion) | CAGR 2025-2035 |
|---|---|
| 0.69 | 7.9% |
South Korea is emerging as a strategic biopharmaceutical manufacturing powerhouse in Asia, with its contract manufacturing market projected to grow from USD 0.61 billion in 2025 to USD 1.52 billion by 2035, registering a strong CAGR of 9.5%. South Korea is home to global CDMO giants-most notably Samsung Biologics and Celltrion-who have aggressively expanded their biomanufacturing campuses with ultra-large-scale capacity and advanced automation. These firms offer one of the lowest cost-per-gram benchmarks globally for mammalian-based biologics, making Korea highly competitive in high-volume, late-stage commercial manufacturing. The Korean Ministry of Food and Drug Safety (MFDS) has consistently aligned its biologics regulations with ICH standards, giving international sponsors confidence in both product quality and regulatory predictability. The Korean government offers robust fiscal incentives and infrastructure grants under its “K-Bio” initiative, which targets biopharma as a strategic export industry. Challenges include rising labor costs in Incheon and Busan and increasing competition from China in early-stage manufacturing. Nonetheless, South Korea remains favored for complex biologic production, particularly by USA and EU sponsors who value its track record in scale, compliance, and time-to-market performance.
| 2025 Value (USD billion) | CAGR 2025-2035 |
|---|---|
| 0.61 | 9.5% |
France is steadily consolidating its position as a key node in the Western European biopharmaceutical outsourcing network, with the market expected to expand from USD 0.59 billion in 2025 to USD 1.18 billion by 2035, marking a CAGR of 7.2%. The outlook is supported by a triad of strategic factors. First, the French government’s Health Innovation 2030 plan includes EUR 7.5 billion in funding for life sciences R&D and manufacturing, which has enabled several mid-size CDMOs to modernize their facilities and expand mammalian cell culture capabilities. Second, France's stringent adherence to EMA GMP protocols, combined with an experienced regulatory workforce, continues to make it a low-risk jurisdiction for European and global sponsors. Third, its central location within the EU allows seamless access to pan-European supply chains. However, challenges remain. France’s labor environment is tightly unionized, leading to higher wage rigidity and slower workforce scale-up compared to peers like Ireland or the Netherlands. Energy prices have also been volatile, particularly for temperature-sensitive bioproduction. Still, the combination of high trust, government backing, and strong pharma-academic linkages ensures that France will retain its relevance, particularly for high-value clinical production and technology transfer projects.
| 2025 Value (USD billion) | CAGR 2025-2035 |
|---|---|
| 0.59 | 7.2% |
Brazil is steadily emerging as Latin America’s most promising biopharmaceutical contract manufacturing market, forecast to grow from USD 0.47 billion in 2025 to USD 1.13 billion by 2035, registering a CAGR of 9.1%. Three core factors underpin this trajectory. First, Brazil’s regulatory authority-ANVISA-has strengthened its biologics review and GMP inspection processes, accelerating alignment with global standards and boosting confidence among multinational sponsors. Second, demand for biologics in Brazil’s public healthcare system (SUS) is rising sharply, driven by national tenders for oncology, diabetes, and autoimmune treatments. This has prompted local CDMOs to expand fill-finish capacity and invest in upstream mammalian cell culture infrastructure. Third, the Brazilian government offers fiscal incentives and import duty waivers for technology transfer and local manufacturing partnerships, making Brazil an attractive base for sponsors aiming to localize production for regional access. Key risks include currency volatility and occasional procurement delays in public sector contracts, which can affect short-term cash cycles. Additionally, Brazil’s logistics infrastructure-while improving-still lags behind global benchmarks in cold-chain resilience. Nonetheless, with a population of over 200 million and a deepening biologics pipeline, Brazil is becoming a strategic node for Latin American contract manufacturing scale-up.
| 2025 Value (USD billion) | CAGR 2025-2035 |
|---|---|
| 0.47 | 9.1% |
Mexico is gaining traction as a secondary manufacturing hub in the Americas, with the biopharmaceutical contract manufacturing market expected to expand from USD 0.42 billion in 2025 to USD 0.95 billion by 2035, translating to a CAGR of 8.4%. Three structural drivers are fueling this growth. First, proximity to the United States and integration under USMCA trade protocols make Mexico an ideal nearshore option for North American sponsors seeking cost-effective GMP capacity without offshore regulatory complexity. Second, COFEPRIS, Mexico’s health regulatory agency, has intensified its international collaboration and now participates in the Pan American Network for Drug Regulatory Harmonization, improving sponsor confidence in quality systems. Third, local CDMOs are moving up the value chain-from packaging and secondary processes to upstream biologics manufacturing-supported by investment from regional conglomerates and global firms. Constraints persist: while labor costs remain attractive, skills shortages in cell culture and analytical development are a known bottleneck. Infrastructure gaps in power reliability and specialized logistics infrastructure also temper rapid expansion. Even so, Mexico’s regulatory gains and geographic advantage are expected to solidify its role as a fast-growing biomanufacturing alternative within the Western Hemisphere.
| 2025 Value (USD billion) | CAGR 2025-2035 |
|---|---|
| 0.42 | 8.4% |
In 2025, Samsung Biologics (18-22% market share) leads the global biopharmaceutical contract manufacturing market, supported by the world’s largest single-site biomanufacturing facility in Songdo and its high-capacity mammalian cell culture systems. Lonza Group (15-19%) follows closely, with strong commercial-scale capabilities across Switzerland, the USA, and Singapore, focusing on monoclonal antibodies, ADCs, and cell and gene therapy production. Thermo Fisher Scientific (13-17%) strengthens its integrated CDMO position through Patheon and recent expansions in Asia, targeting both early-stage and commercial biologics.
WuXi Biologics (10-14%) commands a rapidly growing presence with its "global dual-sourcing" model, offering biologics development and manufacturing services from China, Ireland, and the USA. Catalent Inc. (8-12%) maintains a leadership role in clinical-stage manufacturing and fill-finish operations, with additional scale in mRNA and viral vector production. BoehringerIngelheimBioXcellence (6-9%) capitalizes on end-to-end biologics services from Germany and Austria, particularly in high-volume antibody production.
Fujifilm Diosynth Biotechnologies (4-7%) scales up across Europe and North America, with recent investments in microbial and mammalian platforms. AGC Biologics (3-6%) leverages its global footprint in Japan, the USA, and Denmark to attract mid-sized sponsors. Avid Bioservices (2-4%) focuses on commercial monoclonal antibody production for oncology applications, particularly in the USA market. Rentschler Biopharma (2-3%) builds strength in Europe’s clinical biologics segment through collaborative development models.
| Company Name | Estimated Market Share (%) |
|---|---|
| Samsung Biologics | 18-22% |
| Lonza Group | 15-19% |
| Thermo Fisher Scientific ( Patheon ) | 13-17% |
| WuXi Biologics | 10-14% |
| Catalent Inc. | 8-12% |
| Report Attributes | Details |
|---|---|
| Estimated Market Size (2025) | USD 11.23 billion |
| Projected Market Size (2035) | USD 26.93 billion |
| CAGR (2025 to 2035) | 8.9% |
| Base Year for Estimation | 2024 |
| Historical Period | 2019 to 2024 |
| Forecast Period | 2025 to 2035 |
| Report Parameter | Revenue in USD billion |
| By Platform Type | Mammalian-Based and Microbial-Based |
| By Product Type | Monoclonal Antibodies, Recombinant Protein, Vaccine, Insulin, Growth Factor, Interferons, Others |
| By Application Type | Clinical and Commercial |
| By Therapeutic Area Type | Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders |
| Regions Covered | North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Middle East & Africa |
| Countries Covered | United States, China, Germany, Japan, India, United Kingdom, South Korea, France, Brazil, Mexico |
| Key Players | Samsung Biologics, Lonza Group, Thermo Fisher Scientific ( Patheon ), WuXi Biologics, Catalent Inc., Boehringer Ingelheim BioXcellence , Fujifilm Diosynth Biotechnologies, AGC Biologics, Avid Bioservices , Rentschler Biopharma |
| Additional Attributes | Dollar sales by value, market share analysis by region, and country-wise analysis |
The industry is segmented into Mammalian-Based and Microbial-Based manufacturing platforms.
The industry is segmented into Monoclonal Antibodies, Recombinant Protein, Vaccine, Insulin, Growth Factor, Interferons, and Others.
The industry is categorized into Clinical and Commercial applications.
The industry is segmented into Autoimmune Diseases, Oncology, Metabolic Diseases, Ophthalmology, Cardiovascular Diseases, Infectious Diseases, Neurology, Respiratory Disorders, and Others.
The industry is studied across North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia, and the Middle East & Africa.
The biopharmaceutical contract manufacturing industry is expected to reach USD 11.23 billion in 2025.
The biopharmaceutical contract manufacturing industry is projected to grow to USD 26.93 billion by 2035.
The biopharmaceutical contract manufacturing industry is anticipated to expand at a CAGR of 8.8% from 2025 to 2035.
Oncology, autoimmune diseases, and infectious diseases are among the leading therapeutic areas driving outsourcing demand.
Key companies include Samsung Biologics, Lonza Group, Thermo Fisher Scientific (Patheon), WuXi Biologics, Catalent Inc., and Fujifilm Diosynth Biotechnologies.
Explore Healthcare Services Insights
Biopharmaceutical Contract Manufacturing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
